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Acting as motors, pumps, switches, catalysts, and in numerous 
other roles, proteins perform nearly all the functions of a 
cell. This staggering functional diversity arises from linking 
just 20 amino acids in seemingly endless permutations to 
form polypeptide chains. The sequence of amino acids in 
the polypeptide chain determines a protein’s precise 3-
D structure and biological properties. Cells have evolved 
multiple mechanisms to ensure proper folding, but a number 
of molecular and biophysical events—such as changes in pH 
or temperature, mutations, and oxidation—can disrupt a 
protein’s native shape. 
When polypeptides fail to achieve or maintain their proper 
conformation, they commonly aggregate into abnormal 
“amyloid” structures, which often appear as long, straight, 
unbranched threads—or ﬁbrils—consisting of supercoiled 
“protoﬁlaments.” Amyloid ﬁbrils deﬁne a diverse group 
of degenerative conditions, including amyotrophic lateral 
sclerosis, prion diseases, and Alzheimer and Parkinson 
diseases. In Alzheimer disease, the amyloid ﬁbrils are 
deposited extracellularly; however, in Parkinson and 
Huntington disease, similar amyloid ﬁbrils accumulate in the 
cytoplasm and nucleus of the cell respectively. How amyloid 
formation promotes disease has generated considerable 
debate, though mounting evidence implicates the early 
protoﬁbrillar aggregates as the toxic species. 
In a new study, Leila Luheshi et al. worked with the fruit ﬂy 
Drosophila to identify the intrinsic determinants of amyloid β 
(Aβ) pathogenicity in an animal model of Alzheimer disease. 
(Aβ peptide is a primary component of amyloid plaques in 
the brains of patients with Alzheimer disease.) Determining 
how amyloid formation causes disease requires a better 
understanding of the molecular and biophysical conditions 
that promote protein aggregation. But such an understanding 
has proven technically challenging, in part because protein 
misfolding and aggregation in test tubes can’t replicate 
cellular pathways designed to mitigate the toxic effects of 
these events. Luheshi et al. circumvented this problem by 
integrating computational predictions of protein aggregation 
propensities with in vitro experiments to test the predictions 
and in vivo mutagenesis experiments to link predicted 
aggregation propensity with observed neurodegeneration in 
the ﬂies. 
Aβ peptides have between 39 and 43 amino acid sequences 
(called isoforms), indicated as Aβ39,Aβ 40,and so on. 
Expression of Aβ42 in the Drosophila central nervous system 
produces neuron-damaging deposits and leads to abnormal 
locomotor behavior and shortened life span, as well as 
learning and memory problems. The researchers computed 
the aggregation propensities for each of Aβ42’s 798 possible 
single amino acid substitutions—based on the physical and 
chemical properties of the amino acids—along with those of 
the pathogenic variant E22G Aβ42, which is associated with the 
inherited form of Alzheimer disease. 
They identiﬁed 17 Aβ mutational variants with wide-ranging 
aggregation propensities, expressed them in the Drosophila
central nervous system, and then measured the variants’ 
effects on locomotion and longevity. Fly lines expressing the 
form of the Aβpeptide that has a low aggregation propensity 
and is associated with health in humans (Aβ40) had a life span 
that was equivalent to healthy ﬂies. Those expressing the 
nonmutant (wild-type) Aβ42 peptide, which deposits rapidly 
in the human brain, died sooner; but worse still were the ﬂies 
expressing the highly aggregatory E22G peptide. A few variant 
lines (F20E and 131E/E22G) showed better survival and 
mobility than the wild-type ﬂies (as determined by the number 
of ﬂies reaching the top of a pipette after 45 seconds), while 
other variants shortened the ﬂies’ life spans. 
Overall, the researchers found a clear correlation 
between a variant’s predicted tendency to aggregate and its 
inﬂuence on ﬂy longevity. The same relationship was seen 
between predicted aggregation propensity and locomotion 
(for a representative sample of variant lines), though a 
few variants did not follow this pattern. To understand 
why, the researchers ran additional experiments on two 
peptides—one whose neuronal effects matched its predicted 
aggregation propensity (F20E) and one whose didn’t (131E/
E22G). 
As predicted, F20E reduced the Aβ42 peptide’s tendency 
to aggregate. The F20E Aβ42 peptide aggregated much more 
slowly than the wild-type Aβ42 did in test tubes; and where the 
variant left no deposits in ﬂy brains after 20 days, the wild-type 
peptide left extensive deposits. Since the F20E peptide could 
form amyloid ﬁbrils in the test tube (even though it did so 
slowly) but didn’t leave deposits in the brain, the researchers 
concluded that the F20E mutation inhibited aggregation 
enough for cells to dispose of the aberrant peptide—thus 
accounting for the ﬂies’ enhanced survival and behavior. 
The 131E/E22G peptide, however, showed no correlation 
between predicted aggregation propensity—expected to 
resemble that of the pathogenic E22G peptide—and its 
increased survival and mobility. Nonetheless, the peptide 
aggregated at rates similar to the Alzheimer variant in vitro as 
well as in the ﬂy brains. But because the 131E/E22G peptide 
deposits were not accompanied by cavities in brain tissue—a 
telltale sign of neurodegeneration—the ﬂies showed no 
neurological deﬁcits.
This ﬁnding ﬁts with reports that the density of Aβ plaques 
in elderly patients with Alzheimer disease does not correlate 
with the severity of clinical symptoms—and that the soluble 
protoﬁbrillar aggregates, not the mature amyloid plaques, 
cause neurodegeneration. Recomputing the propensities of 
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The locomotor ability of ﬂies expressing the pathogenic Aβ peptide 
variant, which is associated with Alzheimer disease, is severely 
compromised compared with that of ﬂies carrying less-harmful Aβ 
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each Aβvariant to form these protoﬁbrillar species revealed 
not only an improved overall correlation with toxicity but it 
also brought the previously anomalous 131E/E22G variant in 
line with the prediction algorithm. 
Altogether, these results show that Aβ’s toxic effects in a 
living organism can be predicted based on a computational 
analysis of its tendency to form protoﬁbrillar aggregates. 
And even though cells have evolved multiple mechanisms 
to regulate folding, the researchers argue, it is the intrinsic 
tendency of the peptide’s sequence to aggregate that governs 
its pathological propensity. Though the researchers focused 
on the peptide most closely associated with Alzheimer 
disease, they believe their approach will work for many other 
diseases as well. 
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